Main Line Health Home

Main Line Health | Well Ahead Community

Gilead Announces Results From Phase 2 Study Showing Reduction In Atrial Fibrillation Burden With The Investigational Combination Of Ranolazine And Low-Dose Dronedarone

“There currently are a limited number of safe and effective anti-arrhythmic therapies for AF patients, underscoring the need to evaluate new treatment strategies,” said Peter R. Kowey, MD, William Wikoff Smith Chair in Cardiovascular Research, Lankenau Medical Center and Professor of Medicine and Clinical Pharmacology, Jefferson Medical College, Thomas Jefferson University. More from Biocompare.

Leave a Comment